The price effect of the first Ji third generation does not need to be divided into Sofosvel prices

价格：

600

规格：

400mg+100mg

包装：

6片

The price effect of the first generation of Gilead does not need to be divided into different types
On October 1, US time, it was officially announced that the third generation of Gilead had been approved for marketing. The so-called first generation refers to Sofosbuvir produced by Gilead in the United States, the second generation refers to Hawanib produced by Gilead, and the third generation refers to Iklusha produced by Gilead
Trade name I Colusa, (Bangladesh generic name) chemical name (each pill contains sofosbuvir, velpatasvir),
Indications: Jisandai is suitable for patients with chronic hepatitis C (applicable to all types) for those without cirrhosis or generation Patients with compensated cirrhosis should be treated with icoluxa alone and patients with decompensated cirrhosis should be treated with icoluxa + ribavirin.
The effectiveness and safety of Jisandai have been fully verified in phase-in clinical trials. In three global phase 1 clinical trials, many hepatitis C patients who did not develop cirrhosis or developed compensated cirrhosis completed the entire course of treatment. Among them, up to % of patients could not detect the hepatitis C virus after weeks. the primary clinical endpoint. In another phase 1 clinical trial, 1% of patients with hepatitis C with decompensated cirrhosis who received combination therapy with ribavirin met the primary clinical endpoint. In the trial, no patients who received the treatment experienced serious side effects. As a generic drug of Jisandai, it has the same active ingredients, dosage forms, administration routes and therapeutic effects as Jisandai, so there is no doubt about its efficacy.
Usage and dosage: Take one tablet per day, orally
Common side effects include headache, fatigue, rash, throat discomfort, nausea and vomiting
Specification tablets per box, each tablet contains sofosbuvir + velpatstat Wei
Price per box per course of treatment
On World Hepatitis Day, March 1, the world’s first new hepatitis C drug (Ji’s third generation) generic drug was officially launched in Bangladesh. Developed by Bangladesh's leading pharmaceutical group
According to the different genotypes of hepatitis C virus, hepatitis C can be divided into six subtypes, of which type, type and type account for the majority. Like the new hepatitis C drug Gilead Sciences launched a month ago, it is also a revolutionary hepatitis C cocktail therapy that can directly skip the intermediate link of genotype testing. It can not only treat all six hepatitis C subtypes, but also obtain It is approved for use in combination with ribavirin to treat patients with moderate to severe cirrhosis.
Consult for more informationbr/>